Skip to main content
SpringerLink
Log in
Book cover

Therapy in Pediatric Dermatology pp 339–359Cite as

Hypersensitivity Syndromes

  • Chapter
  • First Online:

  • 1391 Accesses

Abstract

Hypersensitivity syndromes are a group of immune reactions that are produced after exposure to an inciting stimulus. The spectrum of disease ranges from an acute, isolated cutaneous eruption like a fixed drug reaction to fulminant, life-threatening reactions such as Stevens-Johnson syndrome. Most common triggers include medications, infections, or autoimmunity. Many of the syndromes are self-limited, and treatment is targeted toward symptoms relief and/or supportive care.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Sackesen C, Sekerel BE, Orhan F, Kocabas CN, Tuncer A, Adalioglu G. The etiology of different forms of urticaria in childhood. Pediatr Dermatol. 2004;21(2):102.

    Article  PubMed  Google Scholar 

  2. Kane K, Lio P, Stratigos A, Johnson R, editors. Color atlas and synopsis of pediatric dermatology. 2nd ed. New York: McGraw-Hill Professional Publishing; 2009.

    Google Scholar 

  3. Hampel F, Ratner P, Haeusler JM. Safety and tolerability of levocetirizine dihydrochloride in infants and children with allergic rhinitis or chronic urticaria. Allergy Asthma Proc. 2010;31(4):290–5.

    Article  CAS  PubMed  Google Scholar 

  4. Wan KS, Chang YS. Efficacy of leukotriene receptor antagonist with anti-H1 receptor antagonist plus anti-H2 receptor antagonist for treatment of refractory chronic idiopathic urticaria. J Dermatol Treat. 2014;25(6):459–61.

    Article  CAS  Google Scholar 

  5. Greenberger PA. Chronic urticarial: new management options. World Allergy Organ J. 2014;7(1):31.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan E, Bradley MS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized. Placebo-Controlled Study. J Invest Dermatol. 2014. doi:10.1038/jid.2014.512.

    Google Scholar 

  7. Neverman L, Weinberger M. Treatment of chronic urticaria in children with antihistamines and cyclosporine. J Allergy Clin Immunol Pract. 2014;2(4):434–8.

    Article  PubMed  Google Scholar 

  8. Duffey H, Firszt R. Management of acute attacks of hereditary angioedema: role of ecallantide. J Blood Med. 2015;6:115–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137(6):765–70.

    CAS  PubMed  Google Scholar 

  10. Ioseliani M, Lekishvili M. Pediatric drug induced hypersensitivity syndrome: case report. Georgian Med News. 2011;193:90–2.

    Google Scholar 

  11. Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A, et al. General considerations on rapid desensitization for drug hypersensitivity – a consensus statement. Allergy. 2010;65(11):1357.

    Article  CAS  PubMed  Google Scholar 

  12. Lee B, Yu HJ, Kang ES, Lee M, Lee J. Human leukocyte antigen genotypes and trial of desensitization in patients with oxcarbazepine-induced skin rash: a pilot study. Pediatr Neurol. 2014;51(2):207–14.

    Article  PubMed  Google Scholar 

  13. Korkij W, Soltani K. Fixed drug eruption. A brief review. Arch Dermatol. 1984;120(4):520.

    Article  CAS  PubMed  Google Scholar 

  14. Mizukawa Y, Shiohara T. Trauma-localized fixed drug eruption: involvement of burn scars, insect bites and venipuncture sites. Dermatology. 2002;205(2):159.

    Article  PubMed  Google Scholar 

  15. Khaled A, Kharfi M, Ben Hamida M, El Fekih N, El Aidli S, Zeglaoui F, et al. Cutaneous adverse drug reactions in children. A series of 90 cases. Tunis Med. 2012;90(1):45–50.

    PubMed  Google Scholar 

  16. Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol. 2007;17(3):201.

    CAS  PubMed  Google Scholar 

  17. Mizukawa Y, Yamazaki Y, Teraki Y, Hayakawa J, Hayakawa K, Nuriya H, et al. Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am J Pathol. 2002;161(4):1337.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Mahboob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol. 1998;37(11):833–8.

    Article  CAS  PubMed  Google Scholar 

  19. Mahboob A, Haroon TS, Iqbal Z, Iqbal F, Saleemi MA, Munir A. Fixed drug eruption: topical provocation and subsequent phenomena. J Coll Phys Surg Pak. 2006;16(12):747–50.

    Google Scholar 

  20. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272.

    Article  CAS  PubMed  Google Scholar 

  21. Nirken M, High W, Jean-Claude R. Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis. UpToDate. 2014. Available at: http://tinyurl.com/jwdrhce. Accessed 15 Dec 2014.

  22. Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, Kelly JP, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123(2):e297–304.

    Article  PubMed  Google Scholar 

  23. Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2010;85(2):131–8.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Ball R, Ball LK, Wise RP, Braun MM, Beeler JA, Salive ME. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. GrePediatr Infect Dis J. 2001;20(2):219.

    Article  CAS  Google Scholar 

  25. Finkelstein Y, Soon GS, Acuna P, George M, Pope E, Ito S, et al. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011;128(4):723–8.

    Article  PubMed  Google Scholar 

  26. Westly ED, Wechsler HL. Toxic epidermal necrolysis. Granulocytic leukopenia as a prognostic indicator. Arch Dermatol. 1984;120(6):721.

    Article  CAS  PubMed  Google Scholar 

  27. Rzany B, Hering O, Mockenhaupt M, Schröder W, Goerttler E, Ring J, et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 1996;135(1):6.

    Article  CAS  PubMed  Google Scholar 

  28. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136(3):323.

    Article  CAS  PubMed  Google Scholar 

  29. Palmieri TL, Greenhalgh DG, Saffle JR, Spence RJ, Peck MD, Jeng JC, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002;23(2):87.

    Article  CAS  PubMed  Google Scholar 

  30. Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens–Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Intl J Derm. 2014;54:108–15.

    Article  Google Scholar 

  31. Wang YM, Tao YH, Feng T, Li H. Beneficial therapeutic effects of hemoperfusion in the treatment of severe Stevens-Johnson syndrome/toxic epidermal necrolysis: preliminary results. Eur Rev Med Pharmacol Sci. 2014;18(23):3696–701.

    PubMed  Google Scholar 

  32. Patel T, Yosipovitch G. Therapy of pruritus. Expert Opin Pharmacother. 2010;11(10):1673–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Michaud AP, Bauman NM, Burke DK, Manaligod JM, Smith RJ. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Larynoscope. 2004;114(7):1231–6.

    Article  CAS  Google Scholar 

  34. Ubogy Z, Persellin RH. Suppression of erythema nodosum by indomethacin. Acta Derm Venereol. 1982;62(3):265.

    CAS  PubMed  Google Scholar 

  35. Marshall JK, Irvine EJ. Successful therapy of refractory erythema nodosum associated with Crohn’s disease using potassium iodide. Can J Gastroenterol. 1997;11(6):501.

    Article  CAS  PubMed  Google Scholar 

  36. Jauhola O, Ronkainen J, Autio-Harmainen H, Koskimies O, Ala-Houhala M, Arikoski P. Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial. Pediatr Nephrol. 2011;26(12):2159–66.

    Article  PubMed  Google Scholar 

  37. Tamburro JE, Esterly NB. Hypersensitivity syndromes. Adolesc Med. 2001;12(2):323.

    Google Scholar 

  38. Kanai H, Sawanobori E, Kobayashi A, Matsushita K, Sugita K, Higashida K. Early treatment with methylprednisolone pulse therapy combined with tonsillectomy for heavy proteinuric henoch-schönlein purpura nephritis in children. Nephron Extra. 2011;1(1):101–11.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Shin JI, Park JM, Shin YH, Kim JH, Lee JS, Kim PK, et al. Can azathioprine and steroids alter the progression of severe Henoch-Schönlein nephritis in children? Pediatr Nephrol. 2005;20(8):1087–92. Epub 2005 May 12.

    Article  PubMed  Google Scholar 

  40. Singh S, Devidayal, Kumar L, Joshi K, Minz RW, Datta U. Severe Henoch-Schönlein nephritis: resolution with azathioprine and steroids. Rheumatol Int. 2002;22(4):133–7. Epub 2002 Jul 5.

    Article  CAS  PubMed  Google Scholar 

  41. Fagbemi AA, Torrente F, Hilson AJ, Thomson MA, Heuschkel RB, Murch SH. Massive gastrointestinal haemorrhage in isolated intestinal Henoch-Schonlein purpura with response to intravenous immunoglobulin infusion. Eur J Pediatr. 2007;166(9):915–9. Epub 2006 Nov 21.

    Article  PubMed  Google Scholar 

  42. Lee J, Clayton F, Shihab F, Goldfarb-Rumyantzev A. Successful treatment of recurrent Henoch-Schönlein purpura in a renal allograft with plasmapheresis. Am J Transplant. 2008;8(1):228–31.

    CAS  PubMed  Google Scholar 

  43. Du Y, Hou L, Zhao C, Han M, Wu Y. Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil. Pediatr Nephrol. 2012;27(5):765–71.

    Article  PubMed  Google Scholar 

  44. Iqbal H, Evans A. Dapsone therapy for Henoch-Schönlein purpura: a case series. Arch Dis Child. 2005;90(9):985–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Başaran O, Cakar N, Uncu N, Celikel BA, Kara A, Cayci FS, et al. Plasma exchange therapy for severe gastrointestinal involvement of Henoch Schönlein purpura in children. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S-176–80.

    Google Scholar 

  46. Cohen BA. Pediatric dermatology. 4th ed. Baltimore: Elsevier Limited; 2013.

    Google Scholar 

  47. Uziel Y, Silverman ED. Intravenous immunoglobulin therapy in a child with cutaneous polyarteritis nodosa. Clin Exp Rheumatol. 1998;16(2):187–9.

    CAS  PubMed  Google Scholar 

  48. Mori M, Imagawa T, Yoshida Y, Kurozumi H, Ampo K, Mitsuda T, et al. A child of microscopic polyarteritis nodosa effectively treated with intravenous methylprednisolone pulses and serial cyclophosphamide pulse therapy. Ryumachi. 1999;39(4):664–9.

    CAS  PubMed  Google Scholar 

  49. Boehm I, Bauer R. Low-dose methotrexate controls a severe form of polyarteritis nodosa. Arch Dermatol. 2000;136(2):167–9.

    Article  CAS  PubMed  Google Scholar 

  50. Mahr A, Chaigne-Delalande S, De Menthon M. Therapeutic plasma exchange in systemic vasculitis: an update on indications and results. Curr Opin Rheumatol. 2012;24(3):261–6.

    Article  PubMed  Google Scholar 

  51. Kluger N, Guillot B, Bessis D. Ulcerative cutaneous polyarteritis nodosa treated with mycophenolate mofetil and pentoxifylline. J Dermatol Treat. 2011;22(3):175–7.

    Article  CAS  Google Scholar 

  52. Kunnamo I, Kallio P, Pelkonen P, Viander M. Serum-sickness-like disease is a common cause of acute arthritis in children. Acta Paediatr Scand. 1986;75(6):964.

    Article  CAS  PubMed  Google Scholar 

  53. Joubert GI, Hadad K, Matsui D, Gloor J, Rieder MJ. Selection of treatment of cefaclor-associated urticarial, serum sickness-like reactions and erythema multiforme by emergency pediatricians: lack of a uniform standard of care. Can J Clin Pharmacol. 1999;6(4):197.

    CAS  PubMed  Google Scholar 

  54. Tatum AJ, Ditto AM, Patterson R. Severe serum sickness-like reaction to oral penicillin drugs: three case reports. Ann Allergy Asthma Immunol. 2001;86(3):330.

    Article  CAS  PubMed  Google Scholar 

  55. Kuykendall TD, Smoller BR. Lack of specificity in skin biopsy specimens to assess for acute graft-versus-host disease in initial 3 weeks after bone-marrow transplantation. J Am Acad Dermatol. 2003;49(6):1081.

    Article  PubMed  Google Scholar 

  56. Weedon D. The lichenoid reaction pattern (interface dermatitis). In: Weedon’s skin pathology. 3rd ed. Edinburgh: Elsevier Limited; 2010.

    Google Scholar 

  57. Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant. 2006;12(1):31.

    Article  PubMed  Google Scholar 

  58. Furlong T, Leisenring W, Storb R, Anasetti C, Appelbaum FR, Carpenter PA. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Transplant. 2002;8(4):206.

    Article  CAS  PubMed  Google Scholar 

  59. Couriel D, Carpenter PA, Cutler C, Bolaños-Meade J, Treister NS, Gea-Banacloche J, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12(4):375.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Texas Medical School at Houston, Houston, TX, USA

    Marjon Vatanchi & Adelaide A. Hebert

Authors
  1. Marjon Vatanchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adelaide A. Hebert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adelaide A. Hebert .

Editor information

Editors and Affiliations

  1. Stanford University School of Medicine, Stanford, California, USA

    Joyce M.C. Teng

  2. Stanford University School of Medicine, Stanford, California, USA

    Ann L. Marqueling

  3. Pediatric Dermatology, Joe DiMaggio Children’s Hospital, Hollywood, Florida, USA

    Latanya T. Benjamin

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Vatanchi, M., Hebert, A.A. (2017). Hypersensitivity Syndromes. In: Teng, J., Marqueling, A., Benjamin, L. (eds) Therapy in Pediatric Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-43630-2_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43630-2_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43628-9

  • Online ISBN: 978-3-319-43630-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation